The COVID-19 Pandemic – News and Features

Explore how proteomics, AI and microsampling are advancing biomarker discovery. Learn how these innovations are shaping the future of precision medicine.

Researchers from TUM and Helmholtz Munich discovered that even in mild infections, the body prepares T cells that are predisposed to exhaustion. These T cells help the body prepare for potential disease progression.

New research from The University of Texas at Austin could aid in improving whooping cough vaccines to once again push this disease toward eradication by targeting two key weaknesses in the infection.

Researchers have used a clinical-grade antiviral chewing gum to substantially reduce viral loads of two herpes simplex viruses and two influenza A strains in experimental models.

Researchers have uncovered a key cellular mechanism that affects the function of mRNA vaccines and therapeutics, which could pave the way for more effective RNA-based therapies.

Researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment. The drug targets a different viral protein than Paxlovid and works alone.

In this interview, Technology Networks talked to Dr. Stacy Lindborg, president, chief executive officer and board member at IMUNON, Inc., who shares how its PlaCCine® platform could reshape vaccine development.

A large study found pregnant women infected with SARS-CoV-2 had a lower incidence of Long COVID compared to non-pregnant individuals. The research examined data from over 280,000 individuals.

New research findings provide evidence that annual COVID-19 vaccine booster doses continue to be advisable for certain immunocompromised people, researchers at McGill University say.

The unusual flowers seen on Thismia species facilitate specialised pollination mechanisms involving small insects such as fungus gnats.